| http://www.w3.org/ns/prov#value | - Patients were then reclassified using the RS. Annual risks of recurrence and survival were obtained from published meta-analyses of clinical trials, and the study model included costs of the assay and drugs, including chemotherapy (Table 20, Appendix I, Evidence Tables 1, 2, and 5).Table 20Comparison of economic studies.
|
